FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

SPOTLIGHT: Arcoxia vote may have big impact on Novartis


Free newsletter via e-mail
Tools


Novartis will be closely watching today's expert panel session at the FDA on Arcoxia, Merck's hoped-for successor to Vioxx. Their vote could have a big impact on Novartis' chances of successfully developing Prexige. Report

Comments

Yhere is a theoretical but totally plausible difference between vox-2 selective medications that are SULFONES ( Vioxx and Arcoxia) and SULFONAMIDES ( like celebrex and the old BEXTRA). The receptor sites for the cox-2 sulfones are on the surface of the tissues they impact (thereby exposing the tissues to oxidative strss) and the sulfonamises receptor sites are between the bi-lpid layers of the tissues they impact (thereby negating oxidative stress).

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.